Selected research
Industry Research
Virus Bank Manufacturing Industry Research Report 2026
Market perspective
The global Virus Bank Manufacturing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Virus Bank Manufacturing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Virus Bank Manufacturing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Virus Bank Manufacturing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Virus Bank Manufacturing include Clean Cells, Sigma-Aldrich, ReciBioPharm, ViruSure, Cell and Gene, Naobios, TFBS Bioscience, Inc., Catalent Biologics and SK pharmteco, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Virus Bank Manufacturing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Virus Bank Manufacturing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Virus Bank Manufacturing Market by Company
Clean Cells
Sigma-Aldrich
ReciBioPharm
ViruSure
Cell and Gene
Naobios
TFBS Bioscience, Inc.
Catalent Biologics
SK pharmteco
Charles River Laboratories
SGS SA
Virus Bank Manufacturing Segment by Type
Master Virus Seeds Stocks
Working Virus Seeds Stocks
Virus Bank Manufacturing Segment by Application
Biological Vaccines
Gene Therapy
Others
Virus Bank Manufacturing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus Bank Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Virus Bank Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus Bank Manufacturing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Virus Bank Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Master Virus Seeds Stocks
- Working Virus Seeds Stocks
Applications
- Biological Vaccines
- Gene Therapy
- Others
Companies covered
- Clean Cells
- Sigma-Aldrich
- ReciBioPharm
- ViruSure
- Cell and Gene
- Naobios
- TFBS Bioscience, Inc.
- Catalent Biologics
- SK pharmteco
- Charles River Laboratories
- SGS SA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Virus Bank Manufacturing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Master Virus Seeds Stocks
- 2.2.3 Working Virus Seeds Stocks
- 2.3 Virus Bank Manufacturing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Biological Vaccines
- 2.3.3 Gene Therapy
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Virus Bank Manufacturing Breakdown Data by Type
- 3.1 Global Virus Bank Manufacturing Historic Market Size by Type (2021-2026)
- 3.2 Global Virus Bank Manufacturing Forecasted Market Size by Type (2027-2032)
4 Virus Bank Manufacturing Breakdown Data by Application
- 4.1 Global Virus Bank Manufacturing Historic Market Size by Application (2021-2026)
- 4.2 Global Virus Bank Manufacturing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Virus Bank Manufacturing Market Perspective (2021-2032)
- 5.2 Global Virus Bank Manufacturing Growth Trends by Region
- 5.2.1 Global Virus Bank Manufacturing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Virus Bank Manufacturing Historic Market Size by Region (2021-2026)
- 5.2.3 Virus Bank Manufacturing Forecasted Market Size by Region (2027-2032)
- 5.3 Virus Bank Manufacturing Market Dynamics
- 5.3.1 Virus Bank Manufacturing Industry Trends
- 5.3.2 Virus Bank Manufacturing Market Drivers
- 5.3.3 Virus Bank Manufacturing Market Challenges
- 5.3.4 Virus Bank Manufacturing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Virus Bank Manufacturing Players by Revenue
- 6.1.1 Global Top Virus Bank Manufacturing Players by Revenue (2021-2026)
- 6.1.2 Global Virus Bank Manufacturing Revenue Market Share by Players (2021-2026)
- 6.2 Global Virus Bank Manufacturing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Virus Bank Manufacturing Head Office and Area Served
- 6.4 Global Virus Bank Manufacturing Players, Product Type & Application
- 6.5 Global Virus Bank Manufacturing Manufacturers Established Date
- 6.6 Global Virus Bank Manufacturing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Virus Bank Manufacturing Market Size (2021-2032)
- 7.2 North America Virus Bank Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Virus Bank Manufacturing Market Size by Country (2021-2026)
- 7.4 North America Virus Bank Manufacturing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Virus Bank Manufacturing Market Size (2021-2032)
- 8.2 Europe Virus Bank Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Virus Bank Manufacturing Market Size by Country (2021-2026)
- 8.4 Europe Virus Bank Manufacturing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Virus Bank Manufacturing Market Size (2021-2032)
- 9.2 Asia-Pacific Virus Bank Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Virus Bank Manufacturing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Virus Bank Manufacturing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Virus Bank Manufacturing Market Size (2021-2032)
- 10.2 South America Virus Bank Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Virus Bank Manufacturing Market Size by Country (2021-2026)
- 10.4 South America Virus Bank Manufacturing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Virus Bank Manufacturing Market Size (2021-2032)
- 11.2 Middle East & Africa Virus Bank Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Virus Bank Manufacturing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Virus Bank Manufacturing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Clean Cells
- 12.1.1 Clean Cells Company Information
- 12.1.2 Clean Cells Business Overview
- 12.1.3 Clean Cells Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.1.4 Clean Cells Virus Bank Manufacturing Product Portfolio
- 12.1.5 Clean Cells Recent Developments
- 12.2 Sigma-Aldrich
- 12.2.1 Sigma-Aldrich Company Information
- 12.2.2 Sigma-Aldrich Business Overview
- 12.2.3 Sigma-Aldrich Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.2.4 Sigma-Aldrich Virus Bank Manufacturing Product Portfolio
- 12.2.5 Sigma-Aldrich Recent Developments
- 12.3 ReciBioPharm
- 12.3.1 ReciBioPharm Company Information
- 12.3.2 ReciBioPharm Business Overview
- 12.3.3 ReciBioPharm Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.3.4 ReciBioPharm Virus Bank Manufacturing Product Portfolio
- 12.3.5 ReciBioPharm Recent Developments
- 12.4 ViruSure
- 12.4.1 ViruSure Company Information
- 12.4.2 ViruSure Business Overview
- 12.4.3 ViruSure Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.4.4 ViruSure Virus Bank Manufacturing Product Portfolio
- 12.4.5 ViruSure Recent Developments
- 12.5 Cell and Gene
- 12.5.1 Cell and Gene Company Information
- 12.5.2 Cell and Gene Business Overview
- 12.5.3 Cell and Gene Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.5.4 Cell and Gene Virus Bank Manufacturing Product Portfolio
- 12.5.5 Cell and Gene Recent Developments
- 12.6 Naobios
- 12.6.1 Naobios Company Information
- 12.6.2 Naobios Business Overview
- 12.6.3 Naobios Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.6.4 Naobios Virus Bank Manufacturing Product Portfolio
- 12.6.5 Naobios Recent Developments
- 12.7 TFBS Bioscience, Inc.
- 12.7.1 TFBS Bioscience, Inc. Company Information
- 12.7.2 TFBS Bioscience, Inc. Business Overview
- 12.7.3 TFBS Bioscience, Inc. Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.7.4 TFBS Bioscience, Inc. Virus Bank Manufacturing Product Portfolio
- 12.7.5 TFBS Bioscience, Inc. Recent Developments
- 12.8 Catalent Biologics
- 12.8.1 Catalent Biologics Company Information
- 12.8.2 Catalent Biologics Business Overview
- 12.8.3 Catalent Biologics Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.8.4 Catalent Biologics Virus Bank Manufacturing Product Portfolio
- 12.8.5 Catalent Biologics Recent Developments
- 12.9 SK pharmteco
- 12.9.1 SK pharmteco Company Information
- 12.9.2 SK pharmteco Business Overview
- 12.9.3 SK pharmteco Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.9.4 SK pharmteco Virus Bank Manufacturing Product Portfolio
- 12.9.5 SK pharmteco Recent Developments
- 12.10 Charles River Laboratories
- 12.10.1 Charles River Laboratories Company Information
- 12.10.2 Charles River Laboratories Business Overview
- 12.10.3 Charles River Laboratories Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.10.4 Charles River Laboratories Virus Bank Manufacturing Product Portfolio
- 12.10.5 Charles River Laboratories Recent Developments
- 12.11 SGS SA
- 12.11.1 SGS SA Company Information
- 12.11.2 SGS SA Business Overview
- 12.11.3 SGS SA Revenue in Virus Bank Manufacturing Business (2021-2026)
- 12.11.4 SGS SA Virus Bank Manufacturing Product Portfolio
- 12.11.5 SGS SA Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst